Sarcoma News

CHICAGO — Time between therapy regimens can safely be offered to certain children with cancer to promote quality of life and explore goals of care without negatively affecting survival, according to data presented at ASCO Annual Meeting.

A novel immunotherapy involving HER2-specific chimeric antigen receptor T cells produced clinically beneficial results for multiple individuals with advanced sarcomas, according to results of a phase 1 trial published in Nature Cancer.

Jeffrey M. Farma, MD, FACS, has been appointed chair of surgery at Fox Chase Cancer Center.

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.

Chandrajit P. Raut, MD, MSc, has been appointed surgeon-in-chief at Dana-Farber Cancer Institute.

Richard Gorlick, MD, received this year’s ASCO Pediatric Oncology Award, which recognizes an individual who made outstanding contributions to the field.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.

The prospect of screening for multiple cancer types simultaneously through a blood draw or other simple methods has generated tremendous excitement.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.